At Last, AZ’s Imfinzi/Tremelimumab Cancer Combo Shows Survival Benefit

Could Signal First Tremelimumab Approval

 
• By Andrew McConaghie

After five years of failure in NSCLC trials, AstraZeneca’s immunotherapy combo shows survival benefits in POSEIDON.

AstraZeneca
While Tagrisso is a market leader in targeted NSCLC treatment, AZ's immuno-oncology franchise lags behind other competitors.

More from Business

More from Scrip